

(To be published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, 16th January, 2018

ORDER

S.O.269(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes/ revises the price as specified in column (5) of the table herein below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s) specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)	Review Order number and date	Existing SO number and date
(1)	(2)	(3)	(4)	(5)	(6)	(7)
1.	N-acetylcysteine	Sachet 200mg	1 GM	8.16	31015/7/2017- Pricing dated 24.07.2017	2058(E) dated 30.6.2017 (at Sl. No. 408)
2.	Gemcitabine	Powder for Injection 200mg	Each Pack	1063.15	31015/48/2017- Pricing dated 01.12.2017	2058(E) dated 30.6.2017 (at Sl. No. 248)
3.	Amphotericin B - Lipid/ Liposomal	Powder for Injection 50 mg	Each Pack	3402.55	31015/43/2017- Pricing dated 07.9.2017 & 31015/45/2017- Pricing dated 16.11.2017	2059(E) dated 30.6.2017 (at Sl. No. 07)

Note:

- All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.

- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/184/52/2017/F

F. No. 8(52)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 16th January, 2018

ORDER

S. O. 270(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Glimepiride + Metformin Tablet	Each uncouted Bi- Layered tablet contains: Glimepiride IP 1mg, Metformin HCL IP 850mg (As sustained release form)	1 Tablet	M/s Windlas Biotech Ltd. / M/s Intas Pharmaceuticals Pvt. Ltd.	4.89
2.	Glimepiride + Metformin Tablet	Each uncouted Bi- Layered tablet contains: Glimepiride IP 2mg, Metformin HCL IP 850mg (As sustained release form)	1 Tablet	M/s Windlas Biotech Ltd. / M/s Intas Pharmaceuticals Pvt. Ltd.	7.23
3.	Cilnidipine + Metoprolol Tablet	Each film couted Bi- Layered tablet contains: Cilnidipine 10mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (ER)	1 Tablet	M/s Safetab Life Science and Marketer /M/s Intas Pharmaceuticals Pvt. Ltd.	6.98
4.	Escitalopram + Clonazepam Tablet (CENSPRAM MINI)	Each film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 5mg Clonazepam IP 0.5mg	1 Tablet	M/s Accent Pharma / M/s USV Limited	5.73
5.	Ceftriaxone sodium & Tazobactam Sodium Injection	Each combipack contains: Ceftriaxone sodium (sterile) eq. to anhydrous Ceftriaxone 500mg Tazobactam Sodium (sterile) eq. to anhydrous Tazobactam 62.5mg, And	Each pack	M/s Mankind Pharma Ltd.	76.69

		One FFS Ampoule containing Sterile water for injection 5ml			
6.	Olmесartan + Amlodipine Tablet (Tripinom 40)	Each uncoated tablet contains: Olmesartan Medoxomil 40mg, Amlodipine Besylate eq. to Amlodipine 5mg, Hydrochlorothizide 12.5mg	Per Tablet	M/s Accent Pharma / M/s Lupin Ltd.	12.29
7.	Rosuvastatin + Aspirin Capsule (Rozucorn Asp 20 Forte)	Each hard gelatine capsule contains: Rosuvastatin Calcium eq. to Rosuvastatin 20mg (As film coated tablet) Aspirin IP 150mg (as enteric coated tablet)	1 Capsule	M/s Torrent Pharmaceuticals Ltd.	8.78
8.	Rosuvastatin + Aspirin + Clopidogrel Capsule (Unistar Gold 10/75)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As Pellets), Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s GKM New Pharma / M/s Unichem Laboratories Ltd.	11.70
9.	Rosuvastatin + Aspirin + Clopidogrel Capsule (Zyrova Gold 10)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As granules), Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets)	1 Capsule	M/s GKM New Pharma M/s Cadila Healthcare Ltd.	11.70
10.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As granules), Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets)	1 Capsule	M/s GKM New Pharma / M/s Zuventus Healthcare Limited	11.70
11.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As Pellets), Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd /M/s Zydus Healthcare Limited	11.70
12.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As Pellets),	1 Capsule	M/s Synokem Pharmaceuticals Ltd / M/s Mankind Pharma Limited	11.70

		Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)			
13.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg, Aspirin IP 75mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsule	M/s Synokem Pharmaceuticals Ltd / M/s Cadila Pharmaceuticals Limited	11.70
14.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (As film coated tablet), Aspirin IP 75mg (As Gastro – resistant tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet)	1 Capsule	M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Jubilant Life Sciences Limited	11.70
15.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg, Aspirin IP 75mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsule	M/s Synokem Pharmaceuticals Ltd / M/s Eris Lifesciences Ltd.	11.70
16.	Rosuvastatin + Aspirin + Clopidogrel Capsule (Unistar Gold 20/75)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets), Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s GKM New Pharma / M/s Unichem Laboratories Ltd.	18.00
17.	Rosuvastatin + Aspirin + Clopidogrel Capsule (Zyrova Gold 20)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As granules), Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As two film coated tablets)	1 Capsule	M/s GKM New Pharma / M/s Cadila Healthcare Ltd.	18.00
18.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As granules), Aspirin IP 75mg (As enteric Coated Tablets), Clopidogrel Bisulphate IP eq. to	1 Capsule	M/s GKM New Pharma / M/s Zuventus Healthcare Limited	18.00

		Clopidogrel 75mg (As two film coated tablets)			
19.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets), Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd /M/s Zydus Healthcare Limited	18.00
20.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets), Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd/ M/s Mankind Pharma Limited	18.00
21.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As Pellets), Aspirin IP 75mg (As enteric Coated Pellets), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As Pellets)	1 Capsule	M/s Synokem Pharmaceuticals Ltd /M/s Lifestar Pharma Limited	18.00
22.	Rosuvastatin + Aspirin + Clopidogrel Capsule (Jubira Gold 20)	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As film coated tablet), Aspirin IP 75mg (As Gastro – resistant tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet)	1 Capsule	M/s Pure and Cure Healthcare Pvt. Ltd. /M/s Jubilant Life Sciences Limited	18.00
23.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg, Aspirin IP 75mg, Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg	1 Capsule	M/s Synokem Pharmaceuticals Ltd /M/s Eris Lifesciences Ltd.	18.00
24.	Rosuvastatin + Aspirin + Clopidogrel Capsule	Each hard gelatin capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg (As film coated tablet), Aspirin IP 75mg (As enteric coated tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (As film coated tablet)	1 Capsule	M/s Safetab Lifescience M/s Lupin Limited	18.00
25.	Voglibose +	Each uncoated bilayer tablets	1 Tablet	M/s ACME Generics	6.786

	Glimeperide + Metformin Tablet (Glimy MVI)	contains: Voglibose IP 0.2mg, Glimeperide IP 1mg & Metformin Hydrochloride IP 500mg (SR)		/ M/s Dr. Reddy's Laboratories Limited	
26.	Voglibose + Glimeperide + Metformin Tablet (Glimy MV2)	Each uncoated bilayer tablet contains: Voglibose IP 0.2mg, Glimeperide IP 2mg & Metformin Hydrochloride IP 500mg (SR)	1 Tablet	M/s ACME Generics / M/s Dr. Reddy's Laboratories Limited	8.571
27.	Cefixime + Ofloxacin Tablet (Stancef-O Plus)	Each film coated tablet contains: Cefixime Trihydrate eq. to Cefixime Anhydrous IP 200mg, Ofloxacin IP 200mg	1 Tablet	M/s Theon Pharmaceuticals Limited a/ M/s Sun Pharmaceutical Industrial Limited	9.46
28.	Trypsin + Bromelain + Rutoside + Diclofenac Tablet (Volitra Enzo)	Each enteric coated tablet contains: Trypsin BP 48mg, Bromelain 90mg, Rutoside Trihydrate BP 100mg Diclofenac Sodium IP 50mg	1 Tablet	M/s Synokem Pharmaceuticals Limited / M/s Sun Pharmaceuticals Industries Limited	13.85
29.	Gliclazide + Metformin Tablet (GLZ MEX)	Each film coated tablet contains: Gliclazide IP 60mg (In modified release form), Metformin HCL 500mg (extended release form)	1 Tablet	M/s Mascot Health Seris Pvt. Ltd. / M/s Alembic Pharmaceuticals Limited	7.65
30.	Rosuvastatin + Clopidogrel Capsule (Turbovas C)	Each hard gelatine capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 10mg (as film coated tablet), Clopidogrel Bisulphate IP eq. to Clopidogrel 75mg (as 2 film coated tablet)	1 Capsule	M/s Micro Labs Limited	12.95

Note:

- (a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- (b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- (c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned above i.e. who have applied for the same by submitting Form-I for

price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

- (f) The concerned manufacturer of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturer, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (h) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/184/52/2017/F

F. No. 8(52)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director

(To be published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, 16th January, 2018

ORDER

S.O.271(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide order number 31015/67/2017 dated 14th November 2017 passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby set aside its notification bearing number S.O. 1526(E) dated 11th May 2017 regarding the following formulations with immediate effect:

1. Erythromycin Estolate Tablet 250mg
2. Erythromycin Estolate Tablet 500mg
3. Erythromycin Estolate Syrup 125 mg / 5 ml
4. Chloroquine Phosphate Injection 40 mg / ml
(64.5mg eq. to 40mg chloroquine)

PN/184/52/2017/F

F. No. 8(52)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director